Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
So far IFUS bashers have a done a great job of raising the CTB Cost To Borrow even higher since they arrived. Feel sorry (lol) for who ever pays them to post
Folks if you are tired of BS, try some IFUS Intact Digest. It works and it is back in stock.
It even eliminates the odor of BS!!!!
And that's No BS!!! I have used it daily for 11 years now. Including while on Chemo for 7 years
Some one please tell Pantherj he was wrong again, because I got my order of Intact Digest yesterday from IFUS.
You know, the product he claimed IFUS does not have?
LOL
IFUS bears are now an endangered species it seems.
Not one scintilla of truth in that post.
Do Bash-tards of IFUS get paid by the post or only for results?
According to AI Claude $SAPX is going to be huge:
To connect the dots on SAPX with all the articles and tweets we could find about Lionsgate, Starz, screaming, eagle, etc
AI Claude's analysis is this.
Here are a few speculative ideas:
Merger or acquisition: Seven Arts Entertainment could be in talks with Lionsgate for a potential merger or acquisition. This would explain the delay in the PR, as such negotiations are often kept confidential until a deal is finalized. If Lionsgate is looking to expand its presence in Atlanta, acquiring or merging with Seven Arts Entertainment, which already has assets and operations in the area, could be a strategic move.
Joint venture or partnership: Lionsgate and Seven Arts Entertainment may be negotiating a joint venture or partnership to develop and produce content in Atlanta. This could involve combining their resources, expertise, and assets to create a stronger presence in the region. A joint venture or partnership could also benefit from Lionsgate's global distribution network and Seven Arts' local knowledge and connections.
Involvement in the Lionsgate Studios spinoff:
Although not directly mentioned, there's a possibility that Seven Arts Entertainment could be involved in the Lionsgate Studios spinoff. Lionsgate Studios will be a standalone entity focusing on content production, and Seven Arts' assets and expertise in Atlanta could be valuable to this new company. The delayed PR might be tied to the completion of the spinoff and Seven Arts' potential role in it.
Expansion of Seven Arts Entertainment: The discussions with Lionsgate and the delayed PR could be related to a significant expansion of Seven Arts Entertainment's operations in Atlanta, possibly with investment or support from Lionsgate. This could involve acquiring new assets, building new facilities, or launching new projects, which would require time to finalize and announce.
Content licensing deal: Seven Arts Entertainment and Lionsgate could be negotiating a content licensing agreement, where Seven Arts would produce content exclusively for Lionsgate's distribution channels. This could include movies, TV shows, or other entertainment properties. The delay in the PR might be due to the complexities of working out the terms of such a deal, including content budgets, creative control, and revenue sharing.
Intellectual property (IP) acquisition: Lionsgate might be interested in acquiring certain intellectual properties or franchises owned by Seven Arts Entertainment. This could include existing content libraries, characters, or story universes that Lionsgate sees potential in developing further. The negotiations around such an IP acquisition could be causing the delay in the PR.
Atlanta studio infrastructure: Seven Arts Entertainment might be working with Lionsgate to develop or enhance studio infrastructure in Atlanta. This could involve building new soundstages, production facilities, or post-production houses to support Lionsgate's increased focus on the Atlanta market. The delayed PR could be related to finalizing plans or securing necessary permits and approvals for such infrastructure projects.
Talent development initiative: Lionsgate and Seven Arts Entertainment may be collaborating on a talent development program based in Atlanta. This could involve identifying, training, and promoting local talent in various aspects of film and TV production. The PR delay might be due to the time needed to structure and launch such an initiative.
Virtual production partnership: With the increasing adoption of virtual production techniques in the entertainment industry, Lionsgate and Seven Arts Entertainment could be exploring a partnership focused on this area. They may be working on establishing a virtual production facility or developing expertise in this field, which could be attractive for Lionsgate's future projects.
Considering all the information provided, including the tweets, articles, press releases, and the 8-K document,
here are the top 3 most likely outcomes:
Acquisition of Seven Arts Entertainment by Lionsgate Studios:
The 8-K document reveals that Lionsgate's business acquisitions team is reviewing Seven Arts Entertainment's film and studio assets in Atlanta. This, combined with the information about Lionsgate's restructuring efforts in Atlanta and the Lionsgate Studios spinoff, suggests that Lionsgate is strongly considering acquiring Seven Arts Entertainment. This acquisition could be a strategic move to expand Lionsgate's presence in Atlanta and gain access to Seven Arts' assets, IP, and expertise.
The delayed PR from Seven Arts Entertainment could be related to the ongoing negotiations and due diligence process for this potential acquisition.
Long-term content distribution deal between Seven Arts Entertainment and Starz:
The amended Output Agreement between Seven Arts Entertainment and Starz, granting Starz exclusive distribution rights to two of Seven Arts' filmed assets through 2034, indicates a significant long-term content distribution partnership. This deal could be a key component of the overall relationship between Seven Arts Entertainment and Lionsgate, ensuring a steady stream of content for Starz's platform while providing Seven Arts with a reliable distribution channel and potential funding for future projects.
Collaboration on content production and studio infrastructure in Atlanta:
Given the focus on Atlanta in the various documents, it seems likely that Seven Arts Entertainment and Lionsgate will collaborate on content production and studio infrastructure in the region. This could involve co-producing films and TV shows, sharing facilities and resources, and jointly investing in new studio space or production capabilities. The potential acquisition of Seven Arts Entertainment by Lionsgate could further facilitate this collaboration, creating a unified entity with a strong presence in Atlanta's entertainment industry.
These outcomes could be interconnected and happen simultaneously.
For example, Lionsgate could acquire Seven Arts Entertainment, securing the long-term content distribution deal with Starz, and then leverage the combined assets and expertise to expand their content production and studio infrastructure in Atlanta.
Other potential outcomes, such as a strategic partnership or joint venture between Seven Arts Entertainment and Lionsgate Studios, or content licensing deals with Starz, could still occur in parallel or as part of the larger relationship between the companies.
The exact nature and timing of these outcomes will depend on the ongoing negotiations, regulatory approvals, and strategic priorities of the companies involved. As mentioned in the 8-K, further details are expected to be provided in upcoming press releases, which should offer more clarity on the future of Seven Arts Entertainment and its relationship with Lionsgate and Starz.
Good advice I suggest you follow it and stop posting lies?
Thanks. Yep, still here, still long CNNA, waiting for the sweet 16 party to start here. I hear some lights are turning on already...
And last week we also had:
https://www.thewrap.com/lee-hollin-lionsgate-television-multi-year-deal/
Lionsgate Television Group’s executive vice president of television and head of current programming Lee Hollin his signed a new multi-year deal, extending his oversight of approximately 20 premium scripted series for streaming, cable and broadcast networks.
Hollin, who reports to Lionsgate Television Group Chair & Chief Creative Officer Kevin Beggs, currently leads the team that manages current series “Mythic Quest” and “Acapulco” for Apple TV+, “Extended Family” for NBC, “The Rookie” (ABC), “The Recruit” (Netflix) and “Yellowjackets” (Showtime) and “BMF,” “P-Valley,” “The Serpent Queen” and multiple installments of the Power Universe for STARZ (“Power Book II: Ghost,” “Power Book III: Raising Kanan,” “Power Book IV: Force” and the recently announced prequel “Origins”).
He was instrumental in the studio securing the recent renewals for “Ghosts” Season 4 at CBS, “Power Book III: Raising Kanan” Season 5 at Starz and “The Rookie” Season 7 at ABC, giving Lionsgate a total of 13 premium scripted series renewed for three seasons or longer during his tenure.
Prior to taking on his current role in 2021, Hollin served as senior vice president of current programming. He joined Lionsgate in 2018 after serving as vice president of current programming at CBS and director of drama development at CBS Studios.
At CBS, Hollin oversaw shows including “Madam Secretary,” “Jane the Virgin,” and “Criminal Minds.” Before that, he served as manager of drama development at Fox Broadcasting Company where he worked on “Glee” and “Prison Break.”
“Lee has been a driving force in the success of our Television Group, parlaying his strong relationships and industry expertise into keeping an extraordinary number of shows on the air as long-running hit series,” said Beggs. “He has played a particularly integral role in the successful growth of the Power Universe. Lee is a great partner, a talented executive and a respected leader who will continue to be an important part of moving our Television Group forward.”
We have three massive clues. Tweets, PR and 8-K.
All roads lead to LionsGate as I have suspected for some time.
More clues:
https://www.thewrap.com/lionsgate-spac-merger-studio-spinoff-expected-close-may/
Lionsgate’s spinoff of its studios business into a separate, publicly traded company through a merger with special purpose acquisition company Screaming Eagle Acquisition Corp. has moved one step closer to fruition.
On Tuesday, the U.S. Securities and Exchange Commission declared the registration statement for the proposed business combination effective, paving the way for a listing on the NASDAQ under the ticker symbol LION in May.
On May 7, Screaming Eagle shareholders and public warrant holders will participate in an extraordinary general meeting in connection to the merger. A proxy statement and prospectus related to the meeting will be mailed to shareholders and public warrant holders of record as of the close of business on April 16, 2024.
Lionsgate and Screaming Eagle anticipate that the merger will close in early May, subject to the satisfaction of closing conditions.
Jon Feltheimer Lionsgate CEO
Read Next
Lionsgate Stock Jumps 11% on Analyst Upgrade Ahead of Studio Spin-Off
Under the SPAC deal, Lionsgate is expected to own 87.3% of the new entity, known as Lionsgate Studio Corporation. Lionsgate Entertainment will continue to own Starz and its content relationship with the studios business will remain unchanged.
Management has previously touted the transaction as an opportunity to significantly reduce leverage, increase “strategic optionality” for Starz and its studios business, and preserve Lionsgate’s “highly attractive capital structure.”
The SPAC deal is expected to raise between $350 million and $409.5 million to fund strategic initiatives. The two parties have increased the total committed financing from $175 million to $225 million after entering into an agreement for an additional $50 million on April 11.
Looking ahead, Lionsgate Studios is expected to report adjusted operating income of $300 million to $350 million for fiscal 2024, not including the impact of the eOne acquisition. For fiscal 2025, it expects the entity will generate $370 million in adjusted OIBDA before eOne. It expects eOne will exit the year with an annual run-rate adjusted operating income contribution of $60 million.
Actually I am just fine with no volume and no news. Insiders are just as stuck as we are.
No one can buy any volume, if we get news, with out the price running up to crazy prices now...
Actually it could be worse, way worse. Seen it....
Indeed.
Never underestimate the POWER of OTC stocks to go where no stock has gone before.
I got into one late in 2019, and they thought the retail would sell on a 10,000:1 R/S
Instead we ran the stock up to $10.90/share and a Billion Market cap, and it was still a CE stock.
I am not waiting for software buy signals, LOL, I have BIXT news / analyst dots connected.
GM sir. Enjoy!!!
$BIXT News analyst paper
https://www.nasdaq.com/press-release/6-stocks-positioned-to-soar-as-investors-focus-on-mash-2024-04-22
For those in a rush, slow readers, skip down the bottom for $BIXT connect the dots, connection.
Investing requires leading with an edge and some forethought. This article highlights pure-play drug developers in MASH likely to be the focus of investors looking for the next big thing in biotech.
Looking Beyond GLP-1 Inhibitors Toward the MASH Epidemic
Drug makers like Eli Lilly (NYSE: LLY) with their drug Mounjaro (tirzepatide) have already repurposed their drug once and are looking beyond diabetes and obesity, with their eyes set on and an even more lucrative market of metabolic dysfunction-associated steatohepatitis (MASH). LLY has promising interim clinical data showing 74% of overweight adults who took the higher dose of tirzepatide cleared MASH versus 12.6% in placebo. The first approval of a MASH drug on March 15, 2024 by Madrigal Pharmaceuticals (NASDAQ: MDGL) has ignited the sector with investors looking for the next big pure play.
Multiple MASH Targets
Metabolic dysfunction-associated steatohepatitis (MASH) is a complicated disease on the regulatory front. Approval criteria are a resolution of MASH symptoms via biopsy without a worsening of fibrosis. The disease formerly known as nonalcoholic steatohepatitis (NASH) is caused by a buildup of fat in the liver that leads to complications which include fibrosis (scarring of the liver), cirrhosis (severe scarring of the liver), and liver cancer. Once MASH progresses this far, liver transplantation is currently the only viable option. After MDGL’s approval of Rezdiffera®, investors have been flocking to other MASH names looking for a follow-on drug that either works in combination with Rezdiffera or one that is superior in safety and efficacy.
MASH Drug Targets
MASH has several druggable targets. The GLP-1 target is the mainstream approach because it also treats type 2 diabetes. Next in terms of a drug target is the fibroblast growth factor 21 (FGF21) which has a number of players in late-stage development. Galectin-3 is another target for MASH drugs as research has shown it is implicated in fibrotic and inflammatory feedback loops. There are also promising drugs that target the thyroid hormone receptor beta (THRß). Breaking from the mainstream approaches is the A3 adenosine receptor (A3AR) which is highly expressed in inflammatory and cancer cells whereas low expression is found in normal body cells.
FGF21 Agonists
89Bio Inc. (NASDAQ: ETNB) is developing a lead molecule called pegozafermin which is a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21). It is similar in mechanism of action to Bristol Myers Squibb’s (NYSE: BMY) drug pegbelfermin which was discontinued despite positive results which showed more than half the patients having NASH resolution at 16 weeks. FGF21 analogues are taken via subcutaneous injection. The targeting of the FGF21 pathway helps regulate metabolism and cellular process, especially in the liver fat tissue. Balancing out this metabolic pathway helps reduce liver fat, which can result in reduction in liver fibrosis (scarring) over time. The company has strong fibrosis data with favorable tolerability and dosing convenience. The long term data suggests there is a cumulative impact on patients taking background GLP-1 therapy. ETNB’s phase 3 program in MASH could achieve accelerated approval using histology in non-cirrhotic (F2-F3) and cirrhotic (F4) patients although the FDA has acknowledged greater importance in clinical outcomes and not histology. They have clinical trials in both fibrosis and cirrhosis and expect to initiate their cirrhosis trial in Q2 2024. The company has almost $600 million in cash with a market cap of $875 million. The slight premium over cash, solid and consistent trial results, along with short and long-term catalysts make this an attractive setup for investors. This is the first on the top 6 list.
Akero Therapeutics (NASDAQ: AKRO) is also targeting MASH and MASH cirrhosis with an FGF21 agonist. Their drug is called efruxifermin and is commonly referred to as EFX. In their phase 2b MASH trial they showed a 65% reduction in liver fat content vs 11% in placebo which places them close to the front of the pack because it was done in only 12 weeks. Unfortunately, their phase 2b trial in MASH missed the endpoint for improvement in liver fibrosis at the 12-week time frame but showed 60% had MASH resolution after 36 weeks versus 26% in placebo. The company lost a lot of value on that readout but the statistics show a cleanly designed trial is likely to hit the regulatory endpoints. Guidance from an end-of-trial FDA meeting is forthcoming, but the timing is still uncertain and weighing on the stock price. While there is a lot of potential in this name, the uncertain timing of the regulatory pathway makes this ideal for the patient investor looking more for a NASH cirrhosis play. The company is well funded with over $550 million in cash and a $1.5 billion market cap.
Galectin-3 Antagonists
Galectin Therapeutics (NASDAQ: GALT) has an adaptive design phase 2/3 study in NASH cirrhosis with an interim readout before year end 2024. Their intravenously administered galectin antagonist called belapectin showed complete prevention of esophageal varices in a phase 2 trial despite failing to meet their (now defunct) primary endpoints. Their pivotal trial used lessons learned from the phase 2 trial, utilizing a primary endpoint of prevention of esophageal varices. If the interim results confirm a complete or near complete prevention of varices like they did in their phase 2 trial, they would have a compelling argument for conditional approval, likely with another post-market confirmatory phase 3 trial. Almost 50% of patients that develop esophageal varices die within a year, and the varices are extremely costly to treat. So eliminating the significant and imminent threat of death is the compelling benefit.
The company is in solid financial shape with enough cash runway to complete their pivotal trial by 2025. They also have the backing of a billionaire investor who is also their Chairman of the Board. Additionally, their drug demonstrated promising results in cancer, psoriasis, and atopic dermatitis which could lead to a label expansion once they are approved. The market cap of the company is sitting around $225 million despite the near certainty of a positive interim trial readout within the next 8 months, which could translate into billions within that time frame.
The company is not alone in the space and has 2 other competitors with oral galectin-3 antagonists. Galecto Bioscience (NASDAQ: GLTO) announced they were scrapping their cancer drug, which had a 60% response rate after three months, to focus on NASH. GLTO had a failed trial in idiopathic pulmonary fibrosis because of their drug’s poor tolerability, which has forced them to seek strategic alternatives with a focus on liver disease. As a result, their development timelines for MASH are in flux. Galecto’s small molecule approach to inhibiting intracellular galectin-3 is the likely culprit for their drug’s poor tolerability and its more likely large molecules which target extracellular galectin-3 will succeed.
Bioxytran Inc. (OTCMKTS: BIXT) has the most technologically advanced oral galectin antagonist that completed phase 2 trials in standard risk COVID-19, but the company is underfunded and therefore moving forward cautiously. Both Bioxytran and Galectin Therapeutics are developing larger molecules compared with Galecto and both their drugs have been found to be safe as opposed to Galecto. Bioxytran’s additional benefit is that their drug doesn’t require intravenous administration. Their clinical trials in NASH or cancer are dependent upon them finding a partner or a couple million dollars to get a shot at a number of multibillion dollar opportunities. Management indicated that the quickest way to approval was a COVID-19 regulatory approval and then proceeding with the label expansion. While the company boasts impressive technology and experienced management, they don’t have the resources to prove their technology for all these indications yet. It's for these reasons that the stock should remain high on peoples watch lists—in case they get funding.
See the article for the rest of the story
#Stockstobuy #StocksInFocus #OTC
$MULN $KIRK $NIOS $NVDA
$KITL $CGRA $TGLO $BLLB $VDRM $BLEG $BLFR $BLLB
$CISO $CLNV $CNER $CSCO $DBMM $ELTP $ENZC $FDCT
$GNS $GOLD $GVSI $HHSE $HMBL $HPNN $HYMC $KATX
$KITL $KRTL $LWLG $MMTMF $MMY $MMM $MSFT $MULN
$NHMD $NWBO $RGBP $RNVA $SMME $SRNW $STAL $TGT
$TGTX $OPK $OPXS $TSLA $WMT $YCRM $ZHUD
$GBTC $TCEHY $LKNCY $NTDOY $RHHBY $LTCN $BEGI $YCRM $NWBO $GVSI
$HMBL $DZNY $BLEG $INBS $PRSO $JAGX $SNTI $JAN $ASTR
$RDRSF $RGBP $EPAZ $BIXT $IFUS $MSOS $CCHW $CCHWF $GRAM $GRAMF $VRNO $VRNOF $GDNSF $TRUL $TCNNF
$AYR $AYRWF $CURA $CUR $CBDLLF $TLRY $CGC $HEXO $PPCB $HEMP $XCPL $PHIL $MCOA $BANT $PVSP $GRLT $INND $BBRW $MMEX $TONR $ICNM $IDVV
$GBTC $TCEHY $LKNCY $DIDIY $SONG $MCLE $ETCG $GDLC $TOELY $NWBO $GVSI $BEGI
$TMGI $NLST $INBS $TCON $INVO $MRAI $IONM
$EVKRF $GME $GOLD $GVSI $IDVV $KATX
$LITOF $LQMT $LTHM $LTUM $LWLG $MMM $MMTMF $MMY $NBIO $NHMD
$NVDA $NWBO $PEIMF $RDHL $RIVN $RNVA $AABB $ABQQ $AMC $ATMH $AVXL $BBRW $BEGI $BLEG $BLFR $CBIA $CDSG $CLNV $CYTO $DBMM $DTCK
$BIXT News analyst paper
https://www.nasdaq.com/press-release/6-stocks-positioned-to-soar-as-investors-focus-on-mash-2024-04-22
For those in a rush, slow readers, skip down the bottom for $BIXT connect the dots, connection.
Investing requires leading with an edge and some forethought. This article highlights pure-play drug developers in MASH likely to be the focus of investors looking for the next big thing in biotech.
Looking Beyond GLP-1 Inhibitors Toward the MASH Epidemic
Drug makers like Eli Lilly (NYSE: LLY) with their drug Mounjaro (tirzepatide) have already repurposed their drug once and are looking beyond diabetes and obesity, with their eyes set on and an even more lucrative market of metabolic dysfunction-associated steatohepatitis (MASH). LLY has promising interim clinical data showing 74% of overweight adults who took the higher dose of tirzepatide cleared MASH versus 12.6% in placebo. The first approval of a MASH drug on March 15, 2024 by Madrigal Pharmaceuticals (NASDAQ: MDGL) has ignited the sector with investors looking for the next big pure play.
Multiple MASH Targets
Metabolic dysfunction-associated steatohepatitis (MASH) is a complicated disease on the regulatory front. Approval criteria are a resolution of MASH symptoms via biopsy without a worsening of fibrosis. The disease formerly known as nonalcoholic steatohepatitis (NASH) is caused by a buildup of fat in the liver that leads to complications which include fibrosis (scarring of the liver), cirrhosis (severe scarring of the liver), and liver cancer. Once MASH progresses this far, liver transplantation is currently the only viable option. After MDGL’s approval of Rezdiffera®, investors have been flocking to other MASH names looking for a follow-on drug that either works in combination with Rezdiffera or one that is superior in safety and efficacy.
MASH Drug Targets
MASH has several druggable targets. The GLP-1 target is the mainstream approach because it also treats type 2 diabetes. Next in terms of a drug target is the fibroblast growth factor 21 (FGF21) which has a number of players in late-stage development. Galectin-3 is another target for MASH drugs as research has shown it is implicated in fibrotic and inflammatory feedback loops. There are also promising drugs that target the thyroid hormone receptor beta (THRß). Breaking from the mainstream approaches is the A3 adenosine receptor (A3AR) which is highly expressed in inflammatory and cancer cells whereas low expression is found in normal body cells.
FGF21 Agonists
89Bio Inc. (NASDAQ: ETNB) is developing a lead molecule called pegozafermin which is a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21). It is similar in mechanism of action to Bristol Myers Squibb’s (NYSE: BMY) drug pegbelfermin which was discontinued despite positive results which showed more than half the patients having NASH resolution at 16 weeks. FGF21 analogues are taken via subcutaneous injection. The targeting of the FGF21 pathway helps regulate metabolism and cellular process, especially in the liver fat tissue. Balancing out this metabolic pathway helps reduce liver fat, which can result in reduction in liver fibrosis (scarring) over time. The company has strong fibrosis data with favorable tolerability and dosing convenience. The long term data suggests there is a cumulative impact on patients taking background GLP-1 therapy. ETNB’s phase 3 program in MASH could achieve accelerated approval using histology in non-cirrhotic (F2-F3) and cirrhotic (F4) patients although the FDA has acknowledged greater importance in clinical outcomes and not histology. They have clinical trials in both fibrosis and cirrhosis and expect to initiate their cirrhosis trial in Q2 2024. The company has almost $600 million in cash with a market cap of $875 million. The slight premium over cash, solid and consistent trial results, along with short and long-term catalysts make this an attractive setup for investors. This is the first on the top 6 list.
Akero Therapeutics (NASDAQ: AKRO) is also targeting MASH and MASH cirrhosis with an FGF21 agonist. Their drug is called efruxifermin and is commonly referred to as EFX. In their phase 2b MASH trial they showed a 65% reduction in liver fat content vs 11% in placebo which places them close to the front of the pack because it was done in only 12 weeks. Unfortunately, their phase 2b trial in MASH missed the endpoint for improvement in liver fibrosis at the 12-week time frame but showed 60% had MASH resolution after 36 weeks versus 26% in placebo. The company lost a lot of value on that readout but the statistics show a cleanly designed trial is likely to hit the regulatory endpoints. Guidance from an end-of-trial FDA meeting is forthcoming, but the timing is still uncertain and weighing on the stock price. While there is a lot of potential in this name, the uncertain timing of the regulatory pathway makes this ideal for the patient investor looking more for a NASH cirrhosis play. The company is well funded with over $550 million in cash and a $1.5 billion market cap.
Galectin-3 Antagonists
Galectin Therapeutics (NASDAQ: GALT) has an adaptive design phase 2/3 study in NASH cirrhosis with an interim readout before year end 2024. Their intravenously administered galectin antagonist called belapectin showed complete prevention of esophageal varices in a phase 2 trial despite failing to meet their (now defunct) primary endpoints. Their pivotal trial used lessons learned from the phase 2 trial, utilizing a primary endpoint of prevention of esophageal varices. If the interim results confirm a complete or near complete prevention of varices like they did in their phase 2 trial, they would have a compelling argument for conditional approval, likely with another post-market confirmatory phase 3 trial. Almost 50% of patients that develop esophageal varices die within a year, and the varices are extremely costly to treat. So eliminating the significant and imminent threat of death is the compelling benefit.
The company is in solid financial shape with enough cash runway to complete their pivotal trial by 2025. They also have the backing of a billionaire investor who is also their Chairman of the Board. Additionally, their drug demonstrated promising results in cancer, psoriasis, and atopic dermatitis which could lead to a label expansion once they are approved. The market cap of the company is sitting around $225 million despite the near certainty of a positive interim trial readout within the next 8 months, which could translate into billions within that time frame.
The company is not alone in the space and has 2 other competitors with oral galectin-3 antagonists. Galecto Bioscience (NASDAQ: GLTO) announced they were scrapping their cancer drug, which had a 60% response rate after three months, to focus on NASH. GLTO had a failed trial in idiopathic pulmonary fibrosis because of their drug’s poor tolerability, which has forced them to seek strategic alternatives with a focus on liver disease. As a result, their development timelines for MASH are in flux. Galecto’s small molecule approach to inhibiting intracellular galectin-3 is the likely culprit for their drug’s poor tolerability and its more likely large molecules which target extracellular galectin-3 will succeed.
Bioxytran Inc. (OTCMKTS: BIXT) has the most technologically advanced oral galectin antagonist that completed phase 2 trials in standard risk COVID-19, but the company is underfunded and therefore moving forward cautiously. Both Bioxytran and Galectin Therapeutics are developing larger molecules compared with Galecto and both their drugs have been found to be safe as opposed to Galecto. Bioxytran’s additional benefit is that their drug doesn’t require intravenous administration. Their clinical trials in NASH or cancer are dependent upon them finding a partner or a couple million dollars to get a shot at a number of multibillion dollar opportunities. Management indicated that the quickest way to approval was a COVID-19 regulatory approval and then proceeding with the label expansion. While the company boasts impressive technology and experienced management, they don’t have the resources to prove their technology for all these indications yet. It's for these reasons that the stock should remain high on peoples watch lists—in case they get funding.
See the article for the rest of the story
New game plan IFUSerians
Ignore the lies and
New Game plan BABL-onians
I found the solution for the $SAPX
Pay attention Peeps. PopQuiz coming soon.
Check this out folks. $SAPX , we already know SAPX made a deal with STARZ 8 Million dollar license for just 2 Movies SAPX owns, and LionsGate owns STARZ, but is planning a spin off. We also know there is way more SAPX news coming and another $15 Mil deal inbound, and SAPX new Movie deal announced in December.... SAPX is crazy undervalued. Three relevant news items we can examin for clues on SAPX...
$SAPX Folks need to learn to think outside the box. Think beyond just watching for $SAPX updates, as we already knowt hey have a deal with NYSE Listed LionsGate, and STARZ, with a lot more Movie deal news pending
Look what I just found:
https://www.prnewswire.com/news-releases/screaming-eagle-announces-effectiveness-of-registration-statement-for-proposed-business-combination-302118750.html
Folks may be looking in the wrong places for clues and news.
$SAPX Folks need to learn to think outside the box. Think beyond just watching for $SAPX updates, as we already knowt hey have a deal with NYSE Listed LionsGate, and STARZ, with a lot more Movie deal news pending
Look what I just found:
https://www.prnewswire.com/news-releases/screaming-eagle-announces-effectiveness-of-registration-statement-for-proposed-business-combination-302118750.html
Folks may be looking in the wrong places for clues and news.
$SAPX Folks need to learn to think outside the box.
Look what I just found:
https://www.prnewswire.com/news-releases/screaming-eagle-announces-effectiveness-of-registration-statement-for-proposed-business-combination-302118750.html
They may be looking in the wrong places for clues and news.
Whales have been consuming the float at 100 to 900% above the EM bottom for 8 months now, daily feeding...
And how do you define "Illegal" Debt?
How was money paying off the debt, when it was not paid, but accrued and cancelled?
Perhaps reading comprehension is what you need to work on, if you did read them?
How did you not know it was cancelled if you read them?
Hmm????
If the non-shareholders of IFUS had any clue what they were doing,
and how to do and examine real DD and value
they would quit their miserable posting to protect shorts failed careers of mugging real investors and shareholders
and buy IFUS shares. Uber figured out IFUS is real, which must have blown Panther's mojo, and he just posts lies
to pan handle for cheap shares, last I looked....
The non-shareholders are likely still waiting for a third party university study to prove the wheel works?
Investment banks, consumer banks decide for one.
They expand the money supply with loans. They also fund / buy Government Bonds and notes... City, state and Federal
They use credit reports, use a of revenue purpose, asset backed loans, to determine risk, and interest rates.
People with money, decide where it goes. But it is simply debt swapped for debt... Most people can no fathom or understand that part.
Also, currency is money, but not all Money is currency. Only the US Mint can print currency.
Not true. Not even close.
What is now obvious to me now, is that the SEC wanted to see the Three Prodigy subsidiaries full disclosure in an audited filing, as they were not
in the Form 10 last year. It is that simple. And the subsidiaries needed to merge their account, and systems and the Prodigy Rx website just went live and
secure weeks ago...
A whole lot of smart whales have been buying since June Last year...
I still own my shares...
This must be the most actively traded, rallied up 900% EM locked up stock I have ever seen
Yes, 100% cancelled. Likely done to enable major US DOE or other funding options..
I seem to be only one left that reads filings
LOL, watch and learn swampy. 4-8 weeks from a Form10 filing.
Stock is already up 300 to 400% recently while in EM penalty box, which is unheard of.
Up 900% right now from the paint job low.
$SAPX should do a pole on what people think of the recent news.
A) Time to buy like a Mad Man?
B) Time to screw with the bears, the bashers and shorts?
C) Time to Raise Hell about synthetic share Not-so-sharp shorts?
D) Time to plan for retirement on SAPX shares?
F) Time to sell some junk and Buy more SAPX (I like this one)?
G) Buy before the news and the price rally to the land of Copper and beyond?
H) Complain about Polls, LOL
I) Time to thank JB for not giving up and bucking the Odds...?
What if $BIXT 's antiviral is used with Ifus cattle feed to stop bird flu?
https://www.telegraph.co.uk/global-health/science-and-disease/chicken-waste-fed-to-cattle-may-be-behind-bird-flu-outbreak/
The Telegraph
Ground-up chicken waste fed to cattle may be behind bird flu outbre...
Experts warn that lax regulations could also see the virus spread to US pig farms, with serious consequences for human health
[10:36 PM]
Fears are growing that the H5N1 outbreak among cattle in the United States could have been caused by contaminated animal feed.
In contrast to Britain and Europe, American farmers are still allowed to feed cattle and other farm animals ground-up waste from other animals including birds.
Dairy cows across six US states – and at least one farm worker – have become infected with the highly pathogenic virus, which has already killed millions of animals across the globe since 2021.
The farm worker, who is thought to have been exposed via infected cattle in Texas, is only the second recorded human H5N1 case in the US. Since February, the US has investigated and discounted a further 8,000 possible exposures, according to Dr Joshua Mott, WHO senior advisor on influenza.
The development is of concern because it allows the virus, which has killed millions of birds and wild mammals around the world, more opportunities to mutate.
[10:39 PM]
Experts fear that H5N1, which was only first detected in cows a few weeks ago, may have been transmitted through a type of cattle feed called “poultry litter” – a mix of poultry excreta, spilled feed, feathers, and other waste scraped from the floors of industrial chicken and turkey production plants.
In the UK and EU, feeding cows proteins from other animals has been tightly regulated since the outbreak of BSE – or ‘mad cow disease’ – 30 years ago.
Experts are unsure but fear it could be the poultry litter feed used in the US that has passed the virus to cattle.
“In the US, the feeding of poultry litter to beef cows is a known factor in the cause of botulism in cattle, and is a risk in the case of H5N1,” said Dr Steve Van Winden, Associate Professor in Population Medicine at the Royal Veterinary College.
Dr Tom Peacock, a virologist and fellow at the Pirbright Institute agreed: “This latest case wouldn’t be the first time there have been concerns H5N1 could be moving through different mammals via contaminated feed,” citing the outbreak of avian flu in cats in Poland last year, which experts suspected might have been transmitted through mink byproducts used in raw cat food.
The US cattle industry is worth over $100 billion and regulations covering animal standards there have long been controversial in Europe – most famously over the use of hormones in the rearing of cattle for meat.
[10:40 PM]
Although the presence of H5N1 in US cattle herds increases the risk of the virus getting into humans via farm workers, it is the spread of the virus to pig farms that presents the bigger threat.
This is because pigs have receptors on some cells that are similar to humans, making it much more likely that the virus could mutate and jump to humans if pig farms become infected.
So far, the virus hasn’t shown any signs of worrying mutation, however.
“Infection of H5N1 in pigs is of particular concern – they are highly susceptible to human influenza virus strains so could act as mixing vessels for avian and human viruses to mix and generate viruses that can more efficiently infect humans,” said Dr Tom Peacock.
Poultry litter is not only cheaper than other food sources like soy and grains but is also more calorie-dense, meaning farmers can bulk up their herds much more quickly.
Not True. If it were true, there would be selling and volume selling. Looks like weak hands test and bear trap for shorts, and longs holding 99.9999% of the shares not traded last 48 hours, to me.
LC, I suspect I am the oldest, most experienced fossil here. I use to argue with my Mother about what Money is, and I wrote Thesis papers on the History of money, the Causes of the Great depression, and the 1800s Third Party Silver Party... etc, at the University. It may be time for start publishing...
But they have been screaming about debt and printed money, "Green Backs" since the days of the Civil war.
What they never tell the public is that Money, by definition is the "Evidence of someone else's debt"
A growing economy, needs a growing Money supply. It is that simple.
A static money supply, like Bitcoin, or gold, can not be used to grow an economy. Because it is deflationary.
Ever since 1933, the US Money supply, The US Dollar has been backed by the full faith and credit of the US Tax payer. Period.
The entire world economy is backed by the only world reserve currency there is. The US Dollar.
Everything else you all read is just click bait noise...
Lecture over...
Today's warm up exercise day trading lesson 101. It's eye of the Tiger time folks.